## IAP12 Rec'd PCT/PTO 01 MAY 2006

#### IN THE UNITED STATES DESIGNATED/ELECTED OFFICE

International Application No. PCT/EP2004/011551 International Filing Date 14 October 2004 (14.10.2004) Priority Date(s) Claimed 04 November 2003 (04.11.2003) Applicant(s) (DO/EO/US) Hans-Michael EGGENWEILER, ET AL. Title: USE OF THIENOPYRIMIDINES INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §§ 1.56, 1.97 and 1.98 Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 Sir: This information disclosure statement is made in accordance with 37 C.F.R. §§ 1.56, 1.97 and 1.98 as follows: Timing and Fees Under 37 C.F.R. § 1.97(b), no fee or statement is required for filing this information  $\boxtimes$ disclosure statement is filed: within three months of the filing date of a national application other than a CPA under § 1.53(d); X within three months of the actual filing date of the national phase of a PCT application; OR before the mailing of a first substantive office action (including after filing of an RCE). Under 37 C.F.R. § 1.97(c), this information disclosure statement is filed after the periods specified in 37 C.F.R. § 1.97(b), but before the mailing date of: a final rejection under 37 C.F.R. 1.113; termination of prosecution, e.g. Ex Parte Quayle, M.P.E.P § 609(B)(2); OR

a notice of allowance under 37 C.F.R. § 1.311; and

**DOCKET NO.: MERCK-3159** 

		is acco	mpanied by:
			the statement as specified in 37 C.F.R. § 1.97(e) set out below; OR
			a check covering the fee of \$180.00 under 37 C.F.R. § 1.17(p).
			R. § 1.97(d), this information disclosure statement is filed after the mailing lowing actions which have not been withdrawn:
		a final	action under 37 C.F.R. § 1.113;
		termin	ation of prosecution, e.g. Ex Parte Quayle, M.P.E.P § 609(B)(2);
		OR a n	notice of allowance under 37 C.F.R. § 1.311;
	AND i	s filed o	on or before payment of the issue fee; AND is accompanied by:
			tement as specified in 37 C.F.R. § 1.97(e) as set forth below, and the fee of 0 under 37 C.F.R. § 1.17(p).
Statem	nents Ur	nder 37	C.F.R. 1.97(e)
			Each item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application having a mailing date not more than three months prior to the filing date of this information disclosure statement; or
			No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and to the knowledge of the undersigned attorney after making reasonable inquiry, no item of information contained in this information disclosure statement was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing date of the information disclosure statement.
Cited 1	Materia	l <u>s</u>	
		ancesto	of materials listed but not attached were cited in benefit (35 U.S.C. § 120) or application Serial No, on Form 892 by the Examiner and/or Form by the applicant; see 37 C.F.R. § 1.98(d).
		-	of materials listed but not attached were cited in an international search dated February 8, 2005.
		Not rec	quired by 37 CFR § 1.98.
		Copies	of the materials listed are attached (except for the foregoing).
			7

Non-English	Language References					
	An English-language search report or equivalent paper from a foreign patent office is provided indicating the relevance of the cited reference(s).					
$\boxtimes$	A foreign-language search report from a foreign patent office is provided, and pertinent parts are translated substantively below:					
	<ul> <li>X = document of particular relevance when it is taken alone</li> <li>Y = document of particular relevance when it is combined with another such document</li> <li>A = document defining the general state of the art</li> <li>O = non-written disclosure</li> <li>P = intercalated document</li> </ul>					
	<ul> <li>T = document cited to understand the theory or principle underlying the invention</li> <li>E = patent document which has the benefit of a date earlier than the filing date and which was published only on or after this filing date</li> <li>D = cited in the application</li> <li>L = cited for another reason</li> </ul>					
	& = publication of member of same patent family					
$\boxtimes$	Translation of other relevant information on foreign search report					
	In the search report, "Seite" means page, "Seiten" means pages, "Verbindungen der Formel" means Figure of formula, "Beispele" means examples, and "das ganze Dokument" means the entire document, "Spalte" means column, "Zeile" means line, "Abbildungen" means claims, "Anspruch" means example, "Zusammenfassung" means summary, and "Tabelle" means table, and "Tabellen" means tables "in der Anmeldung erwaehnt" means cited in the application, "Schema" means scheme, "und" means and, "Absatz" means break, "Abildung" means figure.					
Other Informa	ation_					
_	ees Due (If Any): ck for \$ covering the fee identified above is attached.					

Please charge to Deposit Account No. 13-3402 \$\_\_\_\_ for the fee identified above.

#### 10/577908 IAP12 Rec'd PCT/FTO 01 MAY 2006

The Commissioner is hereby authorized to charge or credit any overpayment to Deposit Account #13-3402, two copies of this paper are attached for this purpose.

Respectfully submitted,

Anthony J. Zelano, Reg. No. 27,969 Attorney/Agent for Applicants

MILLEN, WHITE, ZELANO & BRANIGAN, P.C.
Arlington Courthouse Plaza I 2200 Clarendon Blvd. Suite 1400 Arlington, Virginia 22201 Telephone: (703) 243-6333 Facsimile: (703) 243-6410

Attorney Docket No.: MERCK-3159

Date: May 1, 2006

AJZ:ssr

**DOCKET NO.: MERCK-3159** 

10/577908

### IAP12 Rec'd PCT/PTO 01 MAY 2006

Please type a plus sign (+) inside this box +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute	for form 1449A/PTO	)		Complete if Known		
				Application Number	USNP of PCT/EP2004/011551	
INFO	RMATION	DIS	CLOSURE	Filing Date	14 October 2004 (14.10.2004)	
STAT	'EMENT B'	Y AI	PPLICANT	First Named Inventor	Hans-Michael EGGENWEILER, et al.	
				Group Art Unit	unknown	
	(use as many she	ets as	necessary)	Examiner Name	unknown	
Sheet 1 of 2		Attorney Docket Number	MERCK-3159			

	U.S. PATENT DOCUMENTS						
Examiner Initials *	Cite No.¹	U.S. Patent Document  Kind Code <sup>2</sup> Number ( <i>if known</i> )		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document  MM-DD-YYYY		
	001	6,133,271	Α	PAMUKCU ET AL.	10-17-2000		
	002	6,130,223	Α	JONAS ET AL.	10-10-2000		
	003	5,948,911	Α	PAMUKCU ET AL.	09-07-1999		
	004	6,482,948	B1	YAMADA ET AL.	11-19-2002		
	005	6,110,920	Α	ROCHUS ET AL.	08-29-2000		

	FOREIGN PATENT DOCUMENTS									
		Foreign Patent Document		Foreign Patent Document		Date of Publication of	Pages, Columns, Lines, Where Relevant			
Examiner Initials*	Cite No.1	Office <sup>3</sup>	Number <sup>4</sup>	Kind Code⁵ ( <i>if known</i> )	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear	T⁵		
	006	EP	1 167 367	A1	NIPPON SODA CO., LTD.	01-02-2002		004		
	007	wo	98/06722	A1	MERCK PATENT GMBH, ET AL.	02-19-1998		005		
	008	wo	03/051346	A2	ALTANA PHARMA AG, ET AL.	06-29-2003				
	009	wo	03/035653		NIPPON SODA CO., LTD, ET AL.	05-01-2003				
			-							

Examiner Signature	Date Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached. Number refers to English language corresponding family member.

# IAP12 Rec'd PCT/FFC 01 MAY 2006

Please type a plus sign (+) inside this box -> +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for	form 1449A/P	то		Complete if Known		
				Application Number	USNP of PCT/EP2004/011551	
INFOR	MATIO	N DISCL	.OSURE	Filing Date	14 October 2004 (14.10.2004)	
STATE	MENT	BY APP	LICANT	First Named Inventor	Hans-Michael EGGENWEILER, et al.	
				Group Art Unit	unknown	
(us	se as many s	sheets as nec	essary)	Examiner Name	unknown	
Sheet	2	of	2	Attorney Docket Number	MERCK-3159	

	NON PATENT LITERATURE DOCUMENTS						
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T 2				
	010	BOEHM R ET AL: "UEBER THIENO-VERBINDUNGEN 5. MITTEILUNG: BASISCH SUBSTITUIERTE THIENOAE2, 3-DUEPYRIMIDINE THIENO COMPOUNDS PART 5: BASICALLY SUBSTITUTED THIENOAE2, 3-DUEPYRIMIDINES" PHARMAZIE, VEB VERLAG VOLK UND GESUNDHEIT. BERLIN, DD, Bd. 41, Nr. 1, 1986, Seiten 23-25, XP001203411; ISSN: 0031-7144					
		SYBERTZ E ET AL: "INGIBITORS OF PDE1 AND PDE5 CGMP PHOSPODIESTERASES: PATENTS AND THERAPEUTIC POTENTIAL" EXPERT OPINION ON THERAPEUTIC PATENTS, ASHLEY PUBLICATIONS, GB, Bd. 7, Nr. 6, 1997, Seiten 631-639, XP002178692; ISSN: 1354-3776					
		, and the state of					
			-				

Examiner		Date	
Signature		Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.